Sodium phenylbutyrate - Acer Therapeutics

Drug Profile

Sodium phenylbutyrate - Acer Therapeutics

Alternative Names: ACER 001

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Acer Therapeutics
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Maple syrup urine disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn urea cycle disorders; Maple syrup urine disease

Most Recent Events

  • 30 Mar 2017 Chemical structure information added
  • 16 May 2016 Acer Therapeutics plans clinical trials for Inborn urea cycle disorders and Maple syrup urine disease in USA (Acer Therapeutics website, May 2016)
  • 10 May 2016 Phase-II clinical trials in Inborn urea cycle disorders in USA (Parenteral) (Acer Therapeutics pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top